CROSSJECT (ALCJ.PA) Stock Price & Overview

EPA:ALCJ • FR0011716265

Current stock price

1.992 EUR
+0.01 (+0.61%)
Last:

The current stock price of ALCJ.PA is 1.992 EUR. Today ALCJ.PA is up by 0.61%. In the past month the price decreased by -2.83%. In the past year, price increased by 46.26%.

ALCJ.PA Key Statistics

52-Week Range0.7199 - 2.695
Current ALCJ.PA stock price positioned within its 52-week range.
1-Month Range1.92 - 2.26
Current ALCJ.PA stock price positioned within its 1-month range.
Market Cap
105.257M
P/E
N/A
Fwd P/E
5.50
EPS (TTM)
-0.23
Dividend Yield
N/A

ALCJ.PA Stock Performance

Today
+0.61%
1 Week
-6.48%
1 Month
-2.83%
3 Months
-9.45%
Longer-term
6 Months +15.55%
1 Year +46.26%
2 Years -36.76%
3 Years -50.69%
5 Years -36.56%
10 Years N/A

ALCJ.PA Stock Chart

CROSSJECT / ALCJ Daily stock chart

ALCJ.PA Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to ALCJ.PA. When comparing the yearly performance of all stocks, ALCJ.PA is one of the better performing stocks in the market, outperforming 85.59% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ALCJ.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to ALCJ.PA. ALCJ.PA has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALCJ.PA Earnings

Next Earnings DateN/A
Last Earnings DateMar 25, 2026
PeriodQ2 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

ALCJ.PA Forecast & Estimates

10 analysts have analysed ALCJ.PA and the average price target is 4.11 EUR. This implies a price increase of 106.52% is expected in the next year compared to the current price of 1.992.

For the next year, analysts expect an EPS growth of 153.27% and a revenue growth 252.41% for ALCJ.PA


Analysts
Analysts86
Price Target4.11 (106.33%)
EPS Next Y153.27%
Revenue Next Year252.41%

ALCJ.PA Groups

Sector & Classification

Index Membership

ALCJ.PA Financial Highlights

Over the last trailing twelve months ALCJ.PA reported a non-GAAP Earnings per Share(EPS) of -0.23. The EPS increased by 13.8% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-11.26M
Industry RankSector Rank
PM (TTM) N/A
ROA -35.89%
ROE -308.38%
Debt/Equity 2.52
Chartmill High Growth Momentum
EPS Q2Q%37.07%
Sales Q2Q%N/A
EPS 1Y (TTM)13.8%
Revenue 1Y (TTM)-100%

ALCJ.PA Ownership

Ownership
Inst Owners0.32%
Shares52.84M
Float40.03M
Ins OwnersN/A
Short Float %N/A
Short RatioN/A

About ALCJ.PA

Company Profile

ALCJ logo image Crossject SA manufactures and markets needle free injection system. The company is headquartered in Dijon, Bourgogne-Franche-Comte and currently employs 103 full-time employees. The company went IPO on 2014-02-20. The firm specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous, and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The firm's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance, and comfort. The firm has industrial partnerships with Hirtenberger and Recipharm. The company provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.

Company Info

IPO: 2014-02-20

CROSSJECT

Parc Mazen-Sully, 6 Rue Pauline Kergomard

Dijon BOURGOGNE-FRANCHE-COMTE FR

Employees: 106

ALCJ Company Website

ALCJ Investor Relations

Phone: 33380549850

CROSSJECT / ALCJ.PA FAQ

What does ALCJ do?

Crossject SA manufactures and markets needle free injection system. The company is headquartered in Dijon, Bourgogne-Franche-Comte and currently employs 103 full-time employees. The company went IPO on 2014-02-20. The firm specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous, and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The firm's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance, and comfort. The firm has industrial partnerships with Hirtenberger and Recipharm. The company provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.


Can you provide the latest stock price for CROSSJECT?

The current stock price of ALCJ.PA is 1.992 EUR. The price increased by 0.61% in the last trading session.


Does ALCJ stock pay dividends?

ALCJ.PA does not pay a dividend.


What is the ChartMill rating of CROSSJECT stock?

ALCJ.PA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


Should I buy ALCJ stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALCJ.PA.


What is the ownership structure of CROSSJECT (ALCJ.PA)?

You can find the ownership structure of CROSSJECT (ALCJ.PA) on the Ownership tab.